See more : JLA Infraville Shoppers Limited (JSHL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shuttle Pharmaceuticals Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Suwary S.A. (SUW.WA) Income Statement Analysis – Financial Results
- Epiroc AB (publ) (EPIPF) Income Statement Analysis – Financial Results
- SC Agrotech Limited (SCAGRO.BO) Income Statement Analysis – Financial Results
- PT Polaris Investama Tbk (PLAS.JK) Income Statement Analysis – Financial Results
- Mahamaya Steel Industries Limited (MAHASTEEL.NS) Income Statement Analysis – Financial Results
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.shuttlepharma.com
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.81K | 66.83K | 60.83K | 54.95K | 18.00K | 18.74K |
| Gross Profit | -6.81K | -66.83K | -60.83K | -54.95K | -18.00K | -18.74K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.52M | 1.49M | 1.02M | 161.77K | 55.57K | -836.00 |
| General & Administrative | 1.05M | 1.07M | 721.18K | 347.75K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.05M | 1.07M | 721.18K | 347.75K | 513.06K | 185.99K |
| Other Expenses | 1.33M | 328.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.89M | 2.55M | 1.74M | 509.52K | 568.63K | 185.15K |
| Cost & Expenses | 5.89M | 2.55M | 1.74M | 509.52K | 586.63K | 203.89K |
| Interest Income | 79.12K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.60M | 969.89K | 50.79K | 39.63K | 30.92K | 10.88K |
| Depreciation & Amortization | 6.81K | 5.97K | 60.83K | 54.95K | 18.00K | 18.74K |
| EBITDA | -3.99M | -4.32M | -1.04M | -711.15K | -577.22K | -183.97K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.89M | -2.55M | -1.74M | -509.52K | -586.63K | -203.89K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -700.34K | -474.17K | 590.86K | -296.21K | -39.51K | -9.70K |
| Income Before Tax | -6.59M | -3.03M | -1.15M | -805.73K | -626.14K | -213.59K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 71.01K | 50.79K | 39.63K | 0.00 | 1.00 |
| Net Income | -6.59M | -3.10M | -1.20M | -845.36K | -626.14K | -213.59K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.41 | -0.30 | -0.09 | -0.06 | -0.05 | -0.02 |
| EPS Diluted | -0.41 | -0.30 | -0.09 | -0.06 | -0.05 | -0.02 |
| Weighted Avg Shares Out | 15.91M | 10.35M | 13.59M | 13.59M | 13.59M | 13.59M |
| Weighted Avg Shares Out (Dil) | 15.91M | 10.35M | 13.59M | 13.59M | 13.59M | 13.59M |
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today first patient...
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today...
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today...
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has...
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate...
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has...
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication...
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory
Source: https://incomestatements.info
Category: Stock Reports